Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | ACACB | O00763 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005383 | 0.92 | LTA4H (0.38) | LTA4HKCNH2SCN9AHDAC6 | |
| SCHEMBL24665373 | 0.92 | LTA4H (0.38) | LTA4HKCNH2SCN9AHDAC6 | |
| SCHEMBL30006191 | 0.89 | SCN9A (0.47) | LTA4HSCN9AHDAC4HDAC6SMN1; SMN2 | |
| SCHEMBL29123609 | 0.89 | SCN9A (0.47) | LTA4HSCN9AHDAC4HDAC6SMN1; SMN2 | |
| SCHEMBL29123464 | 0.89 | SCN9A (0.41) | LTA4HACACBSCN9AP2RX3PPARD | |
| SCHEMBL30006188 | 0.89 | LTA4H (0.46) | LTA4HACACBKCNH2SCN9ATSHR | |
| SCHEMBL24664144 | 0.89 | LTA4H (0.46) | LTA4HACACBKCNH2SCN9ATSHR | |
| SCHEMBL27204690 | 0.88 | LTA4H (0.49) | LTA4HACACBKCNH2P2RX3PPARD | |
| SCHEMBL27171411 | 0.88 | LTA4H (0.49) | LTA4HACACBKCNH2P2RX3PPARD | |
| SCHEMBL24665315 | 0.83 | PPARD (0.42) | LTA4HACACBSCN9AP2RX3PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4628163-A1 | NOVEL HETEROARYL AMINOPROPANOL DERIVATIVES | Novartis AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| EP-4323062-B1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2025-07-23 | — | — | EP | disclosed |
| US-20240199593-A1 | Novel Heteroaryl Aminopropanol Derivatives | NOVARTIS PHARMA AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| EP-4323062-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20220348566-A1 | Novel Heteroaryl Aminopropanol Derivatives | NOVARTIS AG (CH) | 2022-11-03 | — | — | US | disclosed |
| WO-2022219546-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348566-A1 | Novel Heteroaryl Aminopropanol Derivatives | CYP11B2, CYP11B1, CYP3A43 | LTA4H 953/4885ACACB 549/4885KCNH2 1671/4885 |
| US-20240199593-A1 | Novel Heteroaryl Aminopropanol Derivatives | CYP3A43, CYP3A5, CYP51A1 | LTA4H 1384/4885ACACB 961/4885KCNH2 3303/4885 |
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | CYP3A43, CYP11B2, ADRB3 | LTA4H 1006/4885ACACB 648/4885KCNH2 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.